Protein Microarrays from an In Vitro Diagnostics Perspective: Performance Evaluation and Quality Considerations

Performance Evaluation Metrics for Diagnostic Protein Microarrays

In the field of in vitro diagnostics, protein microarrays are typically presented in the form of multi-analyte panel testing, such as autoantibody profiles, allergen-specific antibodies, or cytokine combination assays. Compared with research-use microarrays, diagnostic protein microarrays require more systematic evaluation of metrics including sensitivity, specificity, precision, linear range, limit of detection, cross-reactivity, and interference. When different assays are detected simultaneously on the same microarray, the performance of each marker should be evaluated separately to avoid using the results of a single assay to represent the entire microarray.

Sensitivity and specificity are core metrics. Because multi-analyte panel testing may involve cross-reactivity, antibody or antigen pairing screening is required during microarray design, and the mutual effects between different targets should be evaluated. Precision evaluation should cover different concentration levels, different microarray lots, and different operators to reflect repeatability, intermediate precision, and reproducibility.

Design and Clinical Positioning of Multi-Analyte Panel Testing

Protein microarrays integrate multiple assays on a single carrier, offering the potential advantages of conserving samples and shortening report turnaround time. However, during product design, the intended clinical use must be clearly defined, and a reasonable combination of markers should be determined based on epidemiological evidence, guideline consensus, and clinical needs. Markers should not be added blindly merely because the technology makes it feasible, as this may introduce uncertainty in result interpretation and clinical decision-making.

For diagnostic products, reference intervals or positive cutoff values should be established and validated in the applicable population. Protein levels may differ across populations of different ages, sexes, and regions; therefore, reference interval studies need to consider sample representativeness. When multiple markers are detected simultaneously, issues such as how to report combination results and how to review abnormal results should also be addressed.

Common Issues in Production and Quality Systems

The production of protein microarrays involves steps such as carrier activation, spotting, blocking, drying, and packaging. Fluctuations in any of these steps may affect lot-to-lot consistency. Manufacturers should establish quality control requirements for key materials, intermediates, and finished products, and monitor spotting uniformity, activity retention rate, and stability. Stability studies generally include real-time stability, transport stability, and opened-package stability.

Under the premise of complying with medical device regulatory requirements, product instructions should objectively describe the intended use, limitations, and expected use environment. Expressions such as "most comprehensive" or "absolutely accurate" should not be used in promotional materials, nor should such products be presented as replacements for the clinical diagnostic gold standard. As a multi-analyte screening or auxiliary diagnostic tool, the value of a protein microarray needs to be comprehensively judged in combination with clinical information.

As the in vitro diagnostics regulatory system pays increasing attention to multi-analyte panel testing products, protein microarray development companies should establish complete records in design input, verification and validation, and post-market surveillance to ensure quality control throughout the product lifecycle.